Relapsing Multiple Sclerosis (RMS) | Norton Healthcare

Indication: Relapsing Multiple Sclerosis (RMS)

Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study (EXCHANGE) – BAF312 (siponimod)

Patients previously treated

Drug Study

Principal Investigator: Robert Tillett, M.D.
Norton Neuroscience Institute

Sponsor: Novartis Pharmaceuticals Corp

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.